3/4
05:06 pm
stok
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
Low
Report
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
3/4
07:51 am
stok
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs [Yahoo! Finance]
Low
Report
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs [Yahoo! Finance]
2/25
06:24 am
stok
Stoke Therapeutics (STOK) was upgraded by Wolfe Research to "strong-buy".
Low
Report
Stoke Therapeutics (STOK) was upgraded by Wolfe Research to "strong-buy".
2/24
04:01 pm
stok
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Neutral
Report
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
2/23
06:01 pm
stok
Stoke Therapeutics (NASDAQ:STOK) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
2/18
04:01 pm
stok
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
High
Report
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2/15
10:13 am
stok
Stoke Therapeutics spotlights durable Dravet gains, Phase 3 timeline, and new ADOA program at summit [Yahoo! Finance]
Low
Report
Stoke Therapeutics spotlights durable Dravet gains, Phase 3 timeline, and new ADOA program at summit [Yahoo! Finance]
2/11
07:30 am
stok
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
Low
Report
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
2/7
06:18 am
stok
Stoke Therapeutics (NASDAQ:STOK) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
Low
Report
Stoke Therapeutics (NASDAQ:STOK) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
2/5
05:03 am
stok
Stoke Therapeutics (NASDAQ:STOK) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
2/4
04:27 pm
stok
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]
Medium
Report
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]
2/4
04:01 pm
stok
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Medium
Report
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
1/27
02:22 pm
stok
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA [Yahoo! Finance]
Low
Report
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA [Yahoo! Finance]
1/27
02:05 pm
stok
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA
Low
Report
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA
1/16
04:01 pm
stok
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Low
Report
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
1/15
09:15 am
stok
Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity [Seeking Alpha]
Medium
Report
Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity [Seeking Alpha]
1/12
09:02 am
stok
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Wedbush from $32.00 to $36.00. They now have an "outperform" rating on the stock.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Wedbush from $32.00 to $36.00. They now have an "outperform" rating on the stock.
1/11
02:13 pm
stok
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome [Yahoo! Finance]
Medium
Report
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome [Yahoo! Finance]
1/11
02:00 pm
stok
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
Medium
Report
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
1/6
04:01 pm
stok
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/5
08:33 am
stok
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Chardan Capital from $24.00 to $35.00. They now have a "buy" rating on the stock.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Chardan Capital from $24.00 to $35.00. They now have a "buy" rating on the stock.
1/5
08:02 am
stok
Stoke Therapeutics (NASDAQ:STOK) was given a new $36.00 price target on by analysts at Canaccord Genuity Group Inc.. They now have a "buy" rating on the stock.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) was given a new $36.00 price target on by analysts at Canaccord Genuity Group Inc.. They now have a "buy" rating on the stock.
1/5
07:17 am
stok
Stoke Therapeutics (NASDAQ:STOK) was given a new $35.00 price target on by analysts at Loop Capital.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) was given a new $35.00 price target on by analysts at Loop Capital.
12/16
04:01 pm
stok
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Low
Report
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
12/15
10:58 am
stok
Stoke Therapeutics (NASDAQ:STOK) was given a new $50.00 price target on by analysts at UBS Group AG.
Low
Report
Stoke Therapeutics (NASDAQ:STOK) was given a new $50.00 price target on by analysts at UBS Group AG.